SCOTUS declines to review former Insys founder John Kapoor's conviction
The Supreme Court on Monday said it will not review an appeal on racketeering charges by former opioid kingpin John Kapoor, who was convicted in 2019, and again in 2020, for bribing doctors to sell his company’s fentanyl-based pain medication.
Kapoor’s Insys Therapeutics, made famous for its bribes and dinners to entice doctors to meet prescribing quotas of the firm’s spray-version of a powerful opioid, previously paid $225 million to settle government probes into its wrongdoing.
“Out of pure greed, Insys executives, from John Kapoor on down, bribed doctors to prescribe this powerful and highly addictive narcotic to people who did not need it,” US attorney Andrew Lelling said in a statement when Kapoor was sentenced to 66 months in prison, adding:
Despite increasing public fears of a drug epidemic fueled by pain pill prescriptions, these defendants, led by Kapoor, ploughed ahead, setting weekly quotas for doctors on their payroll, urging them to prescribe Subsys in higher and higher doses, all so they could make millions of dollars at patients’ expense. Their disregard for the public’s health and safety is nothing short of appalling.